Royalty Pharma (RPRX) Return on Capital Employed (2020 - 2026)
Royalty Pharma (RPRX) reported Return on Capital Employed of 8.28% for Q1 2026, down 308.0% on a YoY basis from 3.98% in Q1 2025, and little changed sequentially from 8.27% in Q4 2025.
Royalty Pharma (RPRX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Royalty Pharma (RPRX) has 7 years of Return on Capital Employed data on file, last reported at 8.28% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 308.0% year-over-year to 8.28%; the trailing twelve-month figure through Mar 2026 stood at 8.28% (down 308.0% YoY), and the FY2025 full-year result was 8.53%, up 48.0% from the prior year.
- Return on Capital Employed steadied at 8.28% in Q1 2026, from 8.27% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.36% in Q1 2025 to a low of 1.91% in Q4 2022.
- A 5-year average of 6.81% and a median of 7.66% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 629 bps in 2022 and jumped 744 bps in 2023, its largest moves.
- Tracing RPRX's Return on Capital Employed over 5 years: stood at 1.91% in 2022, then surged by 390 bps to 9.35% in 2023, then dropped by 18 bps to 7.66% in 2024, then rose by 8 bps to 8.27% in 2025, then grew by 0 bps to 8.28% in 2026.
- Business Quant data shows RPRX's Return on Capital Employed at 8.28% in Q1 2026, 8.27% in Q4 2025, and 8.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 8.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.28% |
| Dec 31, 2025 | 8.27% |
| Sep 30, 2025 | 8.37% |
| Jun 30, 2025 | 10.98% |
| Mar 31, 2025 | 11.36% |
| Dec 31, 2024 | 7.66% |
| Sep 30, 2024 | 9.25% |
| Jun 30, 2024 | 5.78% |
| Mar 31, 2024 | 5.82% |
| Dec 31, 2023 | 9.35% |
| Sep 30, 2023 | 2.42% |
| Jun 30, 2023 | 2.75% |
| Mar 31, 2023 | 3.58% |
| Dec 31, 2022 | 1.91% |
| Sep 30, 2022 | 5.69% |
| Jun 30, 2022 | 6.07% |
| Mar 31, 2022 | 8.21% |
| Dec 31, 2021 | 8.20% |
| Sep 30, 2021 | 9.43% |
| Jun 30, 2021 | 11.29% |